Celldex Announces Pricing of $300 Million Public Offering of Common Stock
Celldex Therapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering of 10,345,000 shares at $29.00 per share, expecting gross proceeds of approximately $300 million. The offering aims to fund its commercial readiness and potential launch of barzolvolimab for chronic spontaneous urticaria, continue …